| Methods |
Reviewed data from the HIV PEP Registry, established by the Centers for Disease Control and Prevention, Glaxo Wellcome Inc and Merck & Co Inc. At six weeks post treatment initiation data was collected on the PEP regimen, modifications to the regimen, reports of adverse events or laboratory abnormalities and HIV antibody test results. Serious adverse events were clearly defined. |
| Participants |
Healthcare providers enrolled HCW on a voluntary basis for a six month observation period. From October 1996 to December 1998 492 HCWs were enrolled. Six week follow‐up data was available for 449 (91%). |
| Interventions |
59% received three drugs, 36% two drugs, 1% one drug, 3% four drugs and 1% more than five drugs. |
| Outcomes |
Adverse events
Discontinuation rates |
| Notes |
|
